India's Strides Pharma up after US FDA nod for kidney disease drug

Strides Pharma Science

10/05/2024 09:29

** Shares of Strides Pharma Science  SRID.NS  are up around
2% 
    ** SRID gets US FDA approval for Sevelamer Carbonate
tablets, used to manage elevated phosphate levels in blood of
patients with chronic kidney disease
    ** Stock is set to post its worst week since early Jan, down
4% for the week 
    ** SRID up 31% YTD vs a 11% rise in Nifty Pharma Index
 .NIPHARM  

 (Reporting by Nishit Navin)
 ((nishit.navin@thomsonreuters.com;))